Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

被引：10
|
作者：
Yuan, Zhongyu
Huang, Jia-Jia
Hua, Xin
Zhao, Jian-Li
Lin, Ying
Zhang, Yuan-Qi
Wu, Zhiyong
Zhang, Lehong
Bi, Xiwen
Xia, Wen
Zhong, Yong-Yi
Wang, Shu-Sen
Xu, Fei
Hong, Ruoxi
Jiang, Kuikui
Shi, Yanxia
Xue, Cong
An, Xin
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Oncol, Guangzhou, Peoples R China
[8] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[9] Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
[11] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Dept Med, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
[13] Sun Yat Sen Univ, Ctr Canc, Dept Oncol, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
    Hua, Xin
    Bi, Xi-Wen
    Zhao, Jian-Li
    Shi, Yan-Xia
    Lin, Ying
    Wu, Zhi-Yong
    Zhang, Yuan-Qi
    Zhang, Le-Hong
    Zhang, An-Qing
    Huang, Heng
    Liu, Xin-Mei
    Xu, Fei
    Guo, Ying
    Xia, Wen
    Hong, Ruo-Xi
    Jiang, Kui-Kui
    Xue, Cong
    An, Xin
    Zhong, Yong-Yi
    Wang, Shu-Sen
    Huang, Jia-Jia
    Yuan, Zhong-Yu
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 637 - 645
  • [2] Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
    Sun, Maoben
    Cai, Liangzhen
    Chen, Min
    MEDICINE, 2023, 102 (24) : E33975
  • [3] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan, Yang
    Zhang, Shaohua
    Wang, Tao
    Bian, Li
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Wen, Yi
    Li, Jianbin
    Jiang, Zefei
    CHINESE MEDICAL JOURNAL, 2023, 136 (12) : 1459 - 1467
  • [4] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [5] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [6] First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
    Tripathy, Debu
    Kaufman, Peter A.
    Brufsky, Adam M.
    Mayer, Musa
    Yood, Marianne Ulcickas
    Yoo, Bongin
    Quah, Cheng
    Yardley, Denise
    Rugo, Hope S.
    ONCOLOGIST, 2013, 18 (05): : 501 - 510
  • [7] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
    Schwarzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (02): : 122 - 129
  • [8] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [9] First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer
    Peron, Julien
    Tredan, Olivier
    Ray-Coquard, Isabelle
    Bachelot, Thomas
    Intidhar, Sana
    Galy, Labidi
    Favier, Bertrand
    Treilleux, Isabelle
    Guastalla, Jean-Paul
    BULLETIN DU CANCER, 2012, 99 (02) : E18 - E25
  • [10] Durable and Drastic Response to the Trastuzumab, Letrozole, Abemaciclib, and Goserelin Combination as First-Line Therapy in HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer: A Case Report
    Suwanvecho, Suthida
    Kiatikajornthada, Narongsak
    Phikulsod, Ployploen
    Suwanrusme, Harit
    Jirawatnotai, Siwanon
    CASE REPORTS IN ONCOLOGY, 2025, 18 (01): : 130 - 136
12345